Selected articles
Articles for label Zikán Michal are displayed.. Show all articles
Platinum‑sensitive recurrent ovarian cancer and olaparib maintenance treatment – case report
04/2019 Prof. MUDr. Michal Zikán, Ph.D.
Poly(ADP-ribose) polymerase inhibitors (PARP) represent the most modern approach to ovarian cancer treatment. This treatment is exclusive for individuals harbouring germline or somatic BRCA1 or BRCA2 gene mutations. This case report presents a patient with recurrent ovarian cancer treated with oral PARP inhibitor olaparib as a part of third line treatment. Well tolerated treatment led to excellent long-term survival and quality of life.
ENTIRE ARTICLE
Poly(ADP-ribose) polymerase inhibitors (PARP) represent the most modern approach to ovarian cancer treatment. This treatment is exclusive for individuals harbouring germline or somatic BRCA1 or BRCA2 gene mutations. This case report presents a patient with recurrent ovarian cancer treated with oral PARP inhibitor olaparib as a part of third line treatment. Well tolerated treatment led to excellent long-term survival and quality of life.
Benefits of multidisciplinary approach in the management of ovarian cancer
04/2019 Prof. MUDr. Michal Zikán, Ph.D.
Ovarian cancer is beyond the usual behavior of other solid tumors due to its biological behavior, spreading to serous surfaces, high metabolic demands and high recurrence rates. Although not the most common malignancy, it is a gynecological cancer with the highest mortality. Early or earlier diagnosis, proper therapeutic management, and metabolic care are crucial for the quality of life of patients and their survival. In the diagnosis and other care of a woman with ovarian cancer, experts from other medical specializations should be involved. Therefore, it is essential that they are informed about special characteristics of this type of cancer.
ENTIRE ARTICLE
Ovarian cancer is beyond the usual behavior of other solid tumors due to its biological behavior, spreading to serous surfaces, high metabolic demands and high recurrence rates. Although not the most common malignancy, it is a gynecological cancer with the highest mortality. Early or earlier diagnosis, proper therapeutic management, and metabolic care are crucial for the quality of life of patients and their survival. In the diagnosis and other care of a woman with ovarian cancer, experts from other medical specializations should be involved. Therefore, it is essential that they are informed about special characteristics of this type of cancer.
New treatment possibilities in ovarian cancer patients with BRCA1/2 mutations
04/2017 Doc. MUDr. Michal Zikán, Ph.D.
A new drug using a unique mechanism of action - an intervention in DNA repair - is being introduced into the treatment of ovarian cancer. Olaparib is a drug of the so-called PARP inhibitor group. Interference with the mechanism of DNA repair is particularly effective in BRCA1/2 gene mutation carriers, in whom one of reparation ways is primarily faulty by a germ-line or somatic mutation. Olaparib in the treatment of platinum-sensitive recurrent ovarian cancer in BRCA1/2 mutation carries leads to prolonged progression-free survival and increased overall survival.
ENTIRE ARTICLE
A new drug using a unique mechanism of action - an intervention in DNA repair - is being introduced into the treatment of ovarian cancer. Olaparib is a drug of the so-called PARP inhibitor group. Interference with the mechanism of DNA repair is particularly effective in BRCA1/2 gene mutation carriers, in whom one of reparation ways is primarily faulty by a germ-line or somatic mutation. Olaparib in the treatment of platinum-sensitive recurrent ovarian cancer in BRCA1/2 mutation carries leads to prolonged progression-free survival and increased overall survival.